6 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Versant Vantage III, L.P. | October 2022 | $299M | $299M | 82 |
| Versant Vantage II, L.P. | November 2020 | $254M | $254M | 52 |
| Versant Vantage I, L.P.Filed to raise in 2019, with no closing reported yet. | 2019 | $150M | $0 | 0 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
7 partners are named across this firm’s filings, 6 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Alex Mayweg | Quiet | Biotech & pharma | 5 | 0 |
Classified sectors of Versant Vantage’s own portfolio companies, based on 36 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Versant Vantage’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Versant Venture Capital | 39 | 858 Therapeutics, Aligos Therapeutics, Audentes Therapeutics, BIRD ROCK BIO, Bright Peak Therapeutics, Century Therapeutics, ChanRx, Chinook Therapeutics U.S., CRISPR Therapeutics AG, Euro Ventures 4, Firefly Bio, Graphite Bio, Inception 5, Inception IBD, Jengu Therapeutics, Jnana Therapeutics, Kanyos Bio, Launchpad Therapeutics, Lenz Therapeutics, Lycia Therapeutics, March Therapeutics, Mistral Therapeutics, Monte Rosa Therapeutics, Nexo Therapeutics, Northern Mosaic, Oyster Point Pharma, Pandion Therapeutics Holdco, Pandion Therapeutics, Pep2Tango Therapeutics, Quentis Therapeutics, RayzeBio, Santa Ana Bio, Tempest Therapeutics, Tentarix Biotherapeutics, Travus Therapeutics, Turnstone Biologics, VenatoRx Pharmaceuticals, Ventus Therapeutics U.S., Vividion Therapeutics |
| MPM BioVentures | 2 | Aligos Therapeutics, Firefly Bio |
| Bradley Bolzon | Quiet | Biotech & pharma | 10 | 0 |
| Carlo Rizzuto | Quiet | Biotech & pharma | 10 | 0 |
| Clare Ozawa | Quiet | Biotech & pharma | 8 | 0 |
| Jerel Davis | Quiet | Biotech & pharma | 13 | 0 |
| Robin PraegerNot on the current fund | Quiet | None listed | 0 | 0 |
| Thomas Woiwode | Quiet | Biotech & pharma | 13 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
| Polaris Partners | 2 | Jnana Therapeutics, Quentis Therapeutics |
| Vivo Capital | 2 | Aligos Therapeutics, Kanyos Bio |
| ARCH Venture Partners | 1 | Vividion Therapeutics |
| Caduceus Capital | 1 | Audentes Therapeutics |
| Orbimed Asia Partners | 1 | Audentes Therapeutics |
| Orbimed New Horizons | 1 | Audentes Therapeutics |
| Orbimed Partners | 1 | Audentes Therapeutics |
| Sofinnova Venture Partners | 1 | RayzeBio |
A shared board seat: a company where filings name a Versant Vantage partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.
